Company
About peptidesmedia
Last updated
The independent newsroom for peptides — honest, well-sourced coverage of the science, the safety, and the fast-moving FDA story, with nothing for sale.
Why this exists
The consumer peptide space is a low-trust information vacuum. Vendors and clinics publish conflicted “education”, credentialed voices are largely dismissive, and the fast-moving regulatory story is covered mainly by paywalled trade press or law-firm blogs. Someone researching a peptide cannot easily find a neutral, current, rigorous source. That is the gap.
What we cover
The whole peptide space: research peptides, GLP-1 medicines, collagen, and longevity compounds. We run a continuous regulatory beat, maintain a dated FDA-status tracker, grade the evidence per compound, and report safety findings as they appear in filings, studies, and case reports.
What we will not do
We do not sell anything. We do not publish dosing or self-administration guidance. We do not describe compounding as approval, or conflate drug-regulatory status with anti-doping status. We do not report an animal study as proof of benefit in people.
Rigorous, not dismissive
People will use these compounds whether or not a journalist approves. Our job is to take the question seriously and answer it honestly — including when the honest answer is that nobody knows yet.